TGase Protein Labeling Kits

Transglutaminase Labeling Kits are designed to easily obtain mg amounts of labeled proteins.

Transglutaminase enzymatic labeling requires accessible glutamine or lysine residues on your target protein's surface. Therfore in a first step Substrate Finder Kit (L001) characterizes your target protein: it contains accesible glutamine residues or lysine residues or both or it isn’t a substrate at all.
Substrate Finder Kit (L001) will indicate which Labeling Kit is appropriate to modify your target protein with the desired labels: Biotin, PEG1,088, PEG5,000 or ATTO-488TM, ATTO-532TM , ATTO-550TM, ATTO-647NTM, ATTO-700TM,

Please contact us if you are interested in other labels.

Art. No.
L001 Substrate Finder Kit
1 Kit
310 €


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation




    13.11.2017 - 16.11.2017
    Düsseldorf, Germany

  • Gordon Research Conference on: Transglutaminases in Human Disease Processes

    16.06.2018 - 17.06.2018
    Les Diablerets, Switzerland